Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in chronic low back pain
NCT00876187Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tanezumab in chronic low back pain (CLBP) (5 arms), sponsored by Pfizer. Primary endpoint: Daily Average Low Back Pain Intensity Score at 16 weeks. Started Jun 2009; status: completed.
02
Drugs
tanezumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT00876187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00876187.